Abiomed Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 5/24/2022)
| Balance Sheet | Total Assets | 1,673,390,000.00 | ROE | – |
| Balance Sheet | Total Equity | 1,503,330,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -35,763,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 249,627,000.00 | – | – |
| Cashflow | Operating Cash Flow | 285,390,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.98 | Div. Yield | – |
| Income | Net Income | 136,505,000.00 | P/E | – |
| Income | Shares Outstanding | 45,674,000.00 | P/B | – |
| Income | Total Revenue | 1,031,750,000.00 | P/S | – |
Ratios calculated on: –
Company Description
ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufactures and markets products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In September 2012, the Company announced that its Impella CP product received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for partial circulatory support for up to six hours.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.abiomed.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more